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Abstract
Pulmonary function measures are heritable traits that predict morbidity and mortality and define
chronic obstructive pulmonary disease (COPD). We tested genome-wide association with forced
expiratory volume in 1 s (FEV1) and the ratio of FEV1 to forced vital capacity (FVC) in the
SpiroMeta consortium (n = 20,288 individuals of European ancestry). We conducted a meta-
analysis of top signals with data from direct genotyping (n ≤ 32,184 additional individuals) and in
silico summary association data from the CHARGE Consortium (n = 21,209) and the Health 2000
survey (n ≤ 883). We confirmed the reported locus at 4q31 and identified associations with FEV1
or FEV1/FVC and common variants at five additional loci: 2q35 in TNS1 (P = 1.11 × 10−12), 4q24
in GSTCD (2.18 × 10−23), 5q33 in HTR4 (P = 4.29 × 10−9), 6p21 in AGER (P = 3.07 × 10−15) and
15q23 in THSD4 (P = 7.24 × 10−15). mRNA analyses showed expression of TNS1, GSTCD,
AGER, HTR4 and THSD4 in human lung tissue. These associations offer mechanistic insight into
pulmonary function regulation and indicate potential targets for interventions to alleviate
respiratory disease.
Measures of pulmonary function, such as FEV1 and FEV1/FVC ratio, are important
predictors of population morbidity and mortality1-4 as well as forming the basis for the
diagnosis of COPD. It is well established that pulmonary function is partially genetically
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determined. Twin studies in European and US populations give heritability estimates for
FEV1 as high as 0.77 (refs. 5,6). Longitudinal studies in families suggest that genetic effects
are consistent over time7. Genetic determinants of pulmonary function seem to operate, at
least in part, independent of disease status (such as asthma) and smoking status8, suggesting
that population-based association studies are a viable way to identify key genetic
determinants of lung function.
Adequately powered genome-wide association studies (GWAS) using hundreds of
thousands of common SNPs can identify loci associated with common diseases and the
quantitative traits that underlie them. Collaborative studies achieving sample sizes in excess
of 10,000 have been able to identify associations with common genetic variants with
typically modest effect sizes (usually <0.1 s.d.)9. In the past year, GWAS have reported
association between an intergenic locus at chromosome 4q31 and FEV1/FVC ratio and
COPD, but no large-scale collaborative GWAS have yet been undertaken for lung
function10,11.
If common SNPs underlying lung function have modest effects, very large sample sizes will
be required to identify them. We therefore established the SpiroMeta consortium to facilitate
large-scale meta-analysis of GWAS of lung function. Here we report a meta-analysis of
GWAS in the SpiroMeta consortium, comprising 20,288 individuals of European ancestry,
that tested association between cross-sectional lung function measures and ~2.5 million
genotyped or imputed SNPs (stage 1). We followed up SNPs drawn from the most
significantly associated loci in up to 32,184 individuals by direct genotyping (stage 2a) and
using in silico summary association data relating to a further 22,092 individuals (stage 2b).
These studies confirm the previous reported association at 4q31 and show that five
previously unreported loci are robustly associated with lung function.
RESULTS
Genome-wide association with lung function (stage 1)
We included 14 studies of individuals of European ancestry, with sample sizes totaling
20,288 (Table 1). All individuals had measures of FEV1 and FVC and smoking status
recorded. FEV1 and (separately) FEV1/FVC measures were adjusted for age, age2, sex,
height and ancestry principal components within each study. Genome-wide genotyping was
undertaken with a variety of platforms, and standard quality control measures were used
(Online Methods and Supplementary Table 1). Genotypes were imputed for ~2.5 million
autosomal SNPs from HapMap CEU data and tested for association separately for the
inverse-normal transformed residuals of FEV1 and FEV1/FVC under an additive genetic
model. We carried out meta-analysis of study-specific test statistics using an inverse
variance weighting. We applied genomic control at the study and meta-analysis levels to
avoid overinflation of test statistics owing to population structure or relatedness. Test
statistic inflation before applying genomic control at the meta-analysis level was modest
(λGC = 1.046 for FEV1 and 1.035 for FEV1/FVC). The plots of meta-analysis test statistics
against expected values under the null hypothesis showed an excess of extreme values even
after exclusion of the previously reported11 4q31 locus near HHIP, indicative of additional
loci associated with lung function (Supplementary Fig. 1a,b).
We observed independent regions of association at 17 loci with P < 1 × 10−5 for FEV1 and
23 for FEV1/FVC (Figs. 1a,b and 2), including three regions (4q24 in GSTCD, 4q31 near
HHIP and 15q23 in THSD4) that reached P < 5 × 10−8 in the stage 1 GWAS data alone,
corresponding to a threshold of P < 0.05 after adjusting for 1 million independent tests12.
SNP rs12504628, which was associated with both FEV1/FVC (P = 6.48 × 10−13; Fig. 2c and
Table 2) and FEV1 (P = 1.50 × 10−10; Table 3), lies in an intergenic region upstream of
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HHIP and spanning ~300 kb at 4q31 that has been associated with lung function11,
COPD11 and height9. Our top SNP rs12504628 was in strong linkage disequilibrium (LD;
r2 = 0.97) with the previously reported SNP associated with lung function, rs13147758 (P =
5.30 × 10−10 for FEV1 and P = 1.11 × 10−12 1 for FEV1/FVC in our data), and with SNPs
associated previously with height (rs6854783, r2 = 0.55; rs2055059, r2 = 0.48), suggesting a
role in skeletal growth and development. The hedgehog gene family, of which HHIP is a
member, encodes signaling molecules involved in regulating lung morphogenesis,
suggesting other mechanisms underlying these associations13. This intergenic region also
contains multiple ESTs in human fetal lung (UCSC Browser).
Follow-up analyses (stage 2)
To validate potential associations with lung function, we selected 10 SNPs for further
genotyping in additional studies of European ancestry (stage 2a, 32,184 individuals;
Supplementary Table 2) and 30 SNPs for in silico follow-up (stage 2b; Supplementary Table
3). We obtained the in silico association results from the Health 2000 study (883
individuals) and from the CHARGE Consortium (21,209 individuals). Meta-analysis of the
association results across stages 1, 2a and 2b showed five novel loci reaching genome-wide
significance (P < 5 × 10−8): 2q35 in TNS1, 4q24 in GSTCD, 5q33 in HTR4, 6p21 in AGER
and 15q23 in THSD4 (Table 2 and Fig. 2). A further locus, 6p21 in DAAM2, which was not
selected for further genotyping follow-up in stage 2a, fell just below the threshold for
genome-wide significance for association with FEV1/FVC after meta-analysis across stages
1 and 2b (rs2395730, P = 7.98 × 10−8; Supplementary Table 3 and Table 2).
The strongest association of FEV1 was at 4q24 in GSTCD (rs10516526, P = 2.18 × 10−23;
Table 2 and Fig. 2b). Relatively little is known about GSTCD, but the presence of the C-
terminal α-helical domain common to the glutathione S-transferase (GST) family of
enzymes suggests this protein is involved in cellular detoxification by catalyzing
conjugation of glutathione to products of oxidative stress14. GST enzymes also show
glutathione peroxidase activity regulating the synthesis of prostaglandins and
leukotrienes14. To explore the potential function of GSTCD, we conducted a protein
homology search and identified homology with chloride intracellular channels 1, 3, 4, 5 and
6, suggesting a role for GSTCD beyond the GST enzyme family. Genes in the region also
include INTS12 and NPNT. INTS12 associates with RNA polymerase II and mediates 3′-
end processing of small nuclear RNA15.
The second locus associated with FEV1 was at 2q35, localized to the TNS1 gene
(nonsynonymous coding SNP rs2571445, P = 1.11 × 10−12; Table 2 and Fig. 2a). The
protein this encodes, tensin-1, is an actin-binding protein that contains Src homology 2
domains, suggesting a role in linking cytoskeletal changes with signal transduction16.
Tensin-1 may be functionally involved in cell migration17.
Multiple genes potentially underlie the third locus associated with FEV1 at 5q33. The most
strongly associated SNPs in this region, rs3995090 and rs6889822 (P = 4.29 × 10−9 and P =
8.17 × 10−9; Table 2 and Fig. 2d), are located in an intron in HTR4 and are part of a cluster
of associated SNPs also spanning a SPINK5-like gene, SPINK7, SPINK9 and FBXO38.
HTR4, which encodes 5-hydroxytryptamine receptor-4, is expressed in neurons in the
respiratory pre-Bötzinger complex. Activation of this G protein–coupled receptor protects
spontaneous respiratory activity18. Notably, selective antagonism of HTR4 in human
bronchial strips in vitro attenuates the facilitation of electric field–stimulated cholinergic
contraction by 5-hydroxytryptamine, suggesting a role for HTR4 in mediating airway
caliber19. HTR4 expression has recently been confirmed in airway epithelial type II cells,
where receptor stimulation seems to regulate cytokine responses20. The SPINK family of
serine protease inhibitors may have a role in antimicrobial protection of mucous epithelia21.
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F-box protein-38 (encoded by FBXO38) is a member of a family of proteins that are
believed to mediate protein-protein interactions and protein degradation22.
The strongest association with FEV1/FVC was at 6p21, a gene-rich region of the major
histocompatibility complex (MHC). The extended LD in this region of the MHC prevented
accurate localization of the association signal. However, we observed the peak of
association for a nonsynonymous coding SNP in AGER (rs2070600, P = 3.07 × 10−15;
Table 2 and Fig. 2e), which is a plausible candidate for causal association. AGER, also
known as RAGE, is a multiligand receptor of the immunoglobulin superfamily23. AGER is
highly expressed in the lung, in particular alveolar epithelial cells24, with a potential role in
epithelium–extracellular matrix interactions. Reduced AGER expression has been identified
in individuals with idiopathic pulmonary fibrosis25, and Ager-/- mice develop age-related
pulmonary fibrosis26. Another candidate in this region is the nearby gene NOTCH4, a
member of the family of transmembrane receptors involved in cell fate decisions27. Notch4
is expressed in endothelial cells of the adult mouse lung, where it is believed to regulate
angiogenesis28.
The second identified association with FEV1/FVC was at 15q23, encompassing the THSD4
gene (rs12899618, P = 7.24 × 10−15; Table 2 and Fig. 2f). THSD4 shows homology with
members of the thrombospondin family of extracellular calcium-binding proteins that
modulate cellular attachment, proliferation and migration and have been implicated in
wound healing, inflammation and angiogenesis29.
For each of the loci we reported, the estimated effect sizes were broadly consistent across
the GWAS (Fig. 3).
Association of variants with FVC
We tested the top SNP at each of the loci showing genome-wide significant association (P <
5 × 10−8) with FEV1 or FEV1/FVC for association with the other of the two traits, and with
FVC in the stage 1 studies (Table 3). In addition to being associated with FEV1, rs10516526
in GSTCD was associated with FVC (P = 2.53 × 10−7) but showed no discernible effect on
FEV1/FVC.
Effect of smoking on SNP associations
Adjustment for ever-smoking status in the stage 1 data (Table 3) did not show materially
different effect-size estimates for the associations with the sentinel SNPs in TNS1, GSTCD,
HTR4, AGER, THSD4 or HHIP. Similarly, adjustments for a quantitative measure of
lifetime smoking exposure (pack-years) did not show substantially different effect-size
estimates for the identified SNP associations (data not shown). We also tested the
associations of the top SNPs in TNS1, GSTCD, HTR4, AGER and THSD4 separately in
ever-smokers and never-smokers (Supplementary Table 4); all P values were >0.05 for tests
of interaction between smoking status and these SNPs on lung function.
Gene expression
We determined the mRNA expression profiles of GSTCD, HHIP, THSD4, TNS1, HTR4,
AGER and NOTCH4 in human lung tissue and a series of primary cells. We detected all
transcripts in lung tissue (Supplementary Fig. 2a) and bronchial epithelial cells
(Supplementary Fig. 2b); six transcripts (excluding NOTCH4) were present in human
airway smooth muscle cells. We also detected GSTCD, TNS1, HTR4, AGER and NOTCH4
transcripts in peripheral blood mononuclear cells (Supplementary Fig. 2b). For AGER, we
noted the presence of two PCR products suggesting an unreported splice variant; we
confirmed the presence of the splice variant by sequencing.
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DISCUSSION
Our study reports a meta-analysis of GWAS results from 20,288 participants and follow-up
analyses in 54,276 participants, identifying five novel genome-wide significant loci for
pulmonary function. The regions identified were 4q24 (GSTCD), 2q35 (TNS1) and 5q33
(HTR4) for FEV1, and 6p21 (AGER) and 15q23 (THSD4) for FEV1/FVC. In addition, we
identified a region suggestive of association with FEV1/FVC at 6p21 in DAAM2. The
companion manuscript from the CHARGE Consortium, which reports a GWAS of lung
function in 20,890 participants, also identifies genome-wide significant associations at
GSTCD, HTR4 and AGER30. Both SpiroMeta and CHARGE confirmed the previously
reported association between FEV1 and FEV1/FVC and the 4q31 locus upstream of
HHIP11.
Our findings have several important implications. First, the loci identified were observed in
the whole population studied and were not specific to smokers. The presence of genetic
determinants of lung function that do not depend on prior smoking exposure has been
suggested by previous studies of heritability8. This does not rule out a possible subset of
genetic determinants with effects on lung function that are partially or wholly dependent on
smoking exposure.
We have also attempted to address the issue of genetic factors that influence smoking
behavior. We did not observe any association with the CHRNA3-CHRNA5-CHRNB4 locus
previously reported to be associated with cigarette smoke exposure, lung cancer, peripheral
arterial disease31 and COPD10 (rs1051730, P = 0.23 for FEV1 and 0.56 for FEV1/FVC).
The associations we show in GSTCD, TNS1, HTR4, THSD4 and AGER do not seem to be
attenuated by adjustment for qualitative or quantitative adjustments for smoking exposure.
None of these loci have been implicated in published GWAS of smoking quantity, although
a recent report suggested a role for TSHD4 variants in smoking cessation32.
SNPs showing association with height could also show association with lung function
measures because of incomplete adjustment for height, or because of SNP effects on skeletal
growth with consequences for both height and lung function. The 4q31 locus near HHIP has
shown convincing association with height33. An association was recently reported between
height and rs185819 at 6p21 (ref. 34). Although this association signal was broad, reflecting
the extended LD across this region of the MHC, rs185819 was in weak LD (r2 = 0.069) with
rs2070600 (the sentinel SNP we reported for FEV1/FVC in AGER). These findings leave
open the possibility of shared genetic determinants of growth of pulmonary function and
height, but they do not suggest that our findings are primarily accounted for by inadequate
adjustment for height.
The level of FEV1 at a given time point in an individual depends on two potentially
independent processes: the maximum lung function obtained during development, and the
rate of decline of lung function with age. Lung function reaches a maximum by age 25–35
years35. The populations studied in SpiroMeta cover a wide range of ages except the very
elderly; as expected, FEV1 and FVC values were much lower in children. At least for the
loci we identify, there was little evidence for age-specific effects, suggesting that the genetic
risk factors identified operate across the age ranges; these findings again are in keeping with
those of previous epidemiological studies7. Our analyses were based on cross-sectional
measures of lung function; additional studies in cohorts with longitudinal data will be
needed to identify determinants of the gradients of development and decline in lung function
with age.
The magnitude of the estimated effect on untransformed FEV1 of rs10516526 in GSTCD
was 52 ml per copy of the G allele (frequency, 0.06). This is equivalent to about 3 years of
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FEV1 decline in the nonsmoking population35. Allelic effect sizes on FEV1 of the more
common variants (minor allele frequencies ~0.4) were 19–23 ml for rs3995090 in HTR4 and
rs2571445 in TNS1. Individually, the five loci we describe account for a small proportion
(0.07%–0.14%) of the variance in FEV1 and in FEV1/FVC (Table 2) in the general
population.
After exclusion of the locus near HHIP and the five reported regions, meta-analysis test
statistics still showed an excess of extreme values compared with expected values under the
null, particularly for FEV1. Although we cannot rule out the possibility of residual
population stratification, this indicates the potential to detect further loci associated with
lung function (Supplementary Fig. 1a,b). We have provided a list of the top 2000
associations for FEV1 and for FEV1/FVC (Supplementary Table 5) as a resource to other
investigators.
We imputed nongenotyped SNPs using two software implementations36,37 that share
similar underlying population genetic models38. This methodology facilitates meta-analysis
across different marker sets and improves coverage across the genome, and its utility has
been empirically shown in several large GWAS. However, the power to detect associations
with rare alleles is limited. The loci we report include two relatively infrequent SNPs,
GSTCD (rs10516526, minor allele frequency 0.06) and AGER (rs2070600, minor allele
frequency 0.05); these SNPs were directly genotyped in the majority of stage 1 subjects
(16,514 and 15,386 individuals, respectively).
The associations we report relate to the general population but were of comparable
magnitude after the exclusion of documented cases of asthma or COPD (data not shown).
Although pulmonary function is an important predictor of morbidity and mortality per se, it
will be important to investigate, in appropriately powered studies, whether the risk alleles in
the genes identified in this study act as independent susceptibility markers for COPD or
influence the development of airway obstruction in other diseases, such as asthma.
Our expression profiling studies identified expression of all of the candidate genes in
relevant tissues. Further work is required to elucidate the mechanisms underlying the novel
association signals we describe. In broad terms, however, it is notable that the most probable
candidate genes in the regions identified seem to be involved either in developmental
pathways important for lung growth or in tissue remodeling pathways that might be
expected to alter airway architecture.
In conclusion, the results presented here from the SpiroMeta consortium, together with those
reported by the CHARGE Consortium30, provide strong evidence for newly identified
genetic loci that act as important determinants of pulmonary function.
ONLINE METHODS
Study design
The study consisted of two stages. In stage 1, a meta-analysis was conducted on directly
genotyped and imputed SNPs from 14 studies of individuals of European ancestry, with a
total sample size of 20,288. Details of these studies are given in Table 1. This meta-analysis
provided loci for further genotyping in up to 32,184 individuals of European origin (stage
2a) and in silico comparisons in 22,092 individuals of European origin (stage 2b).
Stage 1 samples
The SpiroMeta consortium consists of 14 GWAS studies: ALSPAC, B58C-T1DGC, B58C-
WTCCC, EPIC (obese and population-based substudies), the EUROSPAN studies (Korcula,
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NSPHS, ORCADES and Vis), FTC (incorporating the FinnTwin16 and Finnish Twin Study
on Aging), KORA S3, NFBC1966, SHIP and TwinsUK (see Table 1 for definitions of
acronyms). The primary analyses on FEV1 and FEV1/FVC included 20,288 individuals of
European descent. The measurements of FEV1 and FVC are described in the Supplementary
Note.
Genome-wide genotyping and quality control
The platforms used were Affymetrix 500K GeneChip array (four studies), Illumina
HumanHap 550 Beadchip (one study), Illumina 317K (four studies), Affymetrix Genome-
Wide SNP6.0 (one study), Illumina Hap370cnv (one study), Illumina Hap300 v1 (one study)
and Illumina Hap300 v2 (two studies). Each individual study applied quality-control criteria
as described in Supplementary Table 1.
Imputation
Imputation of nongenotyped SNPs was undertaken with MACH36 or IMPUTE37 with
preimputation filters and parameters as shown in Supplementary Table 1. SNPs were
excluded if the imputation information, assessed using r2.hat (MACH) or .info (IMPUTE),
was <0.3. In total, 2,705,257 autosomal SNPs were analyzed.
Transformation of data and genotype-phenotype association analysis
Linear regression of age, age2, sex, height and ancestry principal components was
undertaken on FEV1 (milliliters) and FEV1/FVC (percentage). The residuals were
transformed to ranks and subsequently to normally distributed z scores, and were then used
as the phenotype for association testing under an additive genetic model using software
specified in Supplementary Table 1. Appropriate tests for association in related individuals
were applied where necessary, as described in the Supplementary Note.
Meta-analysis of stage 1 data
All stage 1 study effect estimates were corrected using genomic control40 and were oriented
to the forward strand of the NCBI build 36 reference sequence of the human genome,
consistently using the alphabetically higher allele as the coded allele. Study-specific lambda
estimates are shown in Supplementary Table 1. The pooled effect-size estimate and s.e.m.
were computed using inverse variance weighting, and genomic control was applied to the
pooled effect-size estimates. To describe the effect of imperfect imputation on power, we
report ‘N effective’, the sum of the study-specific products of the sample size and the
imputation quality metric. Meta-analysis statistics and figures were produced using R
version 2.7.0.
Selection of SNPs for stage 2
Ten leading SNPs were selected for stage 2a genotyping follow-up (Supplementary Table
2). Thirty leading SNPs were selected for stage 2b in silico exchange, according to P value
(under the threshold of 5 × 10−5), N effective (≥70% of the total sample size) and evidence
from supporting SNPs (Supplementary Table 3).
Stage 2a samples (follow-up genotyped data)
We genotyped 10 SNPs in up to 32,184 individuals from the ADONIX, BHS, BRHS,
BWHHS, Gedling, GS:SFHS, HCS, KORA F4, NFBC1986, Nottingham Smokers and
NSHD studies. The characteristics of the studies are summarized in Table 1, and stage 2a
study information is provided in the Supplementary Note.
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Stage 2b samples (in silico data)
The CHARGE Consortium includes four population-based studies with data on FEV1 and
FEV1/FVC: the Atherosclerosis Risk in Communities (ARIC) study, the Cardiovascular
Health Study (CHS), the Framingham Heart Study (FHS) and the Rotterdam Study (RS).
Details are provided in the companion paper in this issue from the CHARGE Consortium30.
Given differences between the analysis approaches for GWAS adopted by the SpiroMeta
and CHARGE consortia, the CHARGE analyses were undertaken using the analysis
approach adopted by the SpiroMeta consortium (21,209 individuals; larger than the sample
in the companion paper, which excluded subjects with missing or incomplete pack-years
data). We also included 883 population-based subjects from the Health 2000 study in the
stage 2b analysis.
Combined analysis of stage 1 and 2 samples
Meta-analysis of data from stages 1, 2a and 2b was conducted using inverse variance
weighting. We described associations as genome-wide significant if P < 5 × 10−8.
Secondary analyses
To examine the effect of smoking on the causal pathway between the SNPs and the traits of
interest, an adjustment for smoking was applied. The subgroups of ‘ever-smokers’ and
‘never-smokers’ were analyzed separately, and the stratum-specific estimated effects were
combined within each individual study using inverse variance weights before meta-
analyzing over studies. Additional adjustments were undertaken by adjusting for pack-years
among the ever-smokers with these data available, and repeating the analyses.
PCR expression profiling
The mRNA expression profiles of GSTCD, HHIP, THSD4, TNS1, HTR4, AGER and
NOTCH4 were determined in human lung tissue and primary cell samples using RT-PCR,
including RNA from lung (Ambion/ABI), brain, airway smooth muscle cells41 and human
bronchial epithelial cells (Clonetics42). Peripheral blood mononuclear cells were isolated
from whole blood using 6% (w/v) dextran and 42%–51% (v/v) Percoll gradients (Sigma).
Ethical approval for the use of primary cells was obtained from the local ethics committees.
Total RNA was extracted from samples using an RNeasy kit (Qiagen) as directed by the
manufacturer. cDNA was generated from 1 μg of RNA template using random hexamers
and a SuperScript kit (Invitrogen) as directed by the manufacturer. PCR assays were
designed to cross intron-exon boundaries and where splice variation was known, in order to
detect all variants. Primer sequences are given in Supplementary Table 6. All PCR was done
using Platinum Taq High Fidelity (Invitrogen) with 100 ng of cDNA template in a 25-μl
reaction. Cycling conditions were as follows: 94 °C for 3 min, 35 cycles of 94 °C for 45 s,
55 °C for 30 s, and 72 °C for 90 s.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1.
Manhattan plots of association results for FEV1 and FEV1/FVC (analysis stage 1). (a,b)
Manhattan plots ordered by chromosome position. SNPs for which −log10 P > 5 are
indicated in red. The six loci indicated by arrows showed association with FEV1 (a) or
FEV1/FVC (b; P < 5 × 10−8) in the meta-analysis of data from stages 1, 2a and 2b.
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Figure 2.
Regional association plots of six lung function–associated loci. (a–f) Statistical significance
of each SNP on the −log10 scale as a function of chromosome position (NCBI build 36) in
the meta-analysis of stage 1 data alone. The sentinel SNP at each locus is shown in blue; the
correlations (r2) of each of the surrounding SNPs to the sentinel SNP are shown in the
indicated colors. The six loci included are those that showed association with FEV1 or
FEV1/FVC (P < 5 × 10–8) in the meta-analysis of data from stages 1, 2a and 2b. The
combined P values for all stages are indicated by arrows. The relevant trait (FEV1 or FEV1/
FVC ratio) is indicated for each plot. For rs12504628, the plot shows only the association of
FEV1/FVC; this SNP was associated (P < 5 × 10−8) with both FEV1 and FEV1/FVC. Fine-
scale recombination rate is plotted in blue39. Combined P value from stages 1 and 2a only;
SNP rs3995090 had low imputation quality in the CHARGE Consortium data and so was
not included in stage 2b.
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Figure 3.
Forest plots of the stage 1 meta-analysis for the six lung function–associated loci. Each of
the SNPs included in the figure showed genome-wide significant association (P < 5 × 10−8)
with either FEV1 or FEV1/FVC in the data from stages 1, 2a and 2b. The plots show the
meta-analysis of the stage 1 data for each sentinel SNP. The contributing effect (transformed
beta) from each study is shown by a square, with confidence intervals indicated by
horizontal lines. The contributing weight of each study to the meta-analysis is indicated by
the size of the square. The combined meta-analysis estimate in the stage 1 data is shown at
the bottom of each graph.
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